According to Associação Brasileira do Sono (Brazilian Sleep Association), 43% of the Brazilian population reports some degree of insomnia and other sleep disorders. ANVISA (Brazilian Health Surveillance Agency) reports that between 2007 and 2010 calming and sleeping controlled medication (Rx drugs) with active ingredients clonazepam, bromazepan and alprazolam featured amongst the top-selling drugs commercialised in Brazil. This is to say that a significant number of Brazilians suffer from...
Euromonitor International's Calming and Sleeping in Brazil report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2007-2011, allowing you to identify the sectors driving growth. Forecasts to 2016 illustrate how the market is set to change.
Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.
Why buy this report?
* Get a detailed picture of the Calming and Sleeping market;
* Pinpoint growth sectors and identify factors driving change;
* Understand the competitive environment, the market’s major players and leading brands;
* Use five-year forecasts to assess how the market is predicted to develop.
Euromonitor International has over 40 years' experience of publishing market research reports, business reference books and online information systems. With offices in London, Chicago, Singapore, Shanghai, Vilnius, Dubai, Cape Town, Santiago, Sydney, Tokyo and Bangalore and a network of over 800 analysts worldwide, Euromonitor International has a unique capability to develop reliable information resources to help drive informed strategic planning.